What is Nektar Therapeutics Price-to-Free-Cash-Flow?
As of today (2024-04-27), Nektar Therapeutics's share price is $1.32.
Nektar Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.02. Hence, Nektar Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Nektar Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Nektar Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 13.40. The lowest was 7.71. And the median was 9.74.
NKTR's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.20% per year.
During the past 13 years, Nektar Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 26.50% per year. The lowest was -72.40% per year. And the median was 2.20% per year.
Nektar Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Nektar Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nektar Therapeutics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Nektar Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's Price-to-Free-Cash-Flow falls into.
Nektar Therapeutics's Share Price of today is $1.32. Nektar Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Nektar Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Nektar Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 